The answer so far
It is not established that BPC-157 capsules work better for gut problems or that injections work better for injuries. The routes expose the body differently, but available evidence does not reliably compare their effects in people. A claim that the peptide resists stomach fluid does not tell us how much of a particular capsule is absorbed or whether it helps.123
On this page
- Why do people compare the two?
- What does “stable in stomach fluid” mean?
- Has an oral BPC-157 study been registered?
- What do animal and other human studies tell us?
- Is an injection necessarily better absorbed or safer?
- Do “arginate”, “acetate” or “stable” settle the question?
- Where should I go next?
- Sources
Why do people compare the two?
People looking into BPC-157 may hear that a swallowed product is meant for the digestive tract, while an injection is meant for a tendon or joint. The idea is understandable: a capsule encounters the digestive tract and an injection bypasses it. But where a product enters the body does not by itself tell us where it acts or which outcome it will improve. An effect in the gut might be local or involve the wider body; an injected substance may also move beyond the injection site. These possibilities need to be measured, not assumed.13
- ReleaseDoes the particular formulation release the peptide where expected?
- StabilityHow much remains intact under the conditions being studied?
- Absorption or local actionDoes it reach the blood, or is a local gut effect the question?
- OutcomeDoes the tested product make a meaningful difference in people, and what harms occur?
What does “stable in stomach fluid” mean?
Researchers have described BPC-157 as resistant to breakdown in gastric juice under laboratory conditions. That is a reason to investigate, not a measurement of a finished capsule in a human body. After swallowing, a substance must be released from its formulation. For an effect through the bloodstream, it must also cross a biological barrier, such as the gut wall. It may be broken down or altered along the way. Stability, absorption and clinical benefit are three separate questions. A product might act locally without substantial bloodstream absorption, but contact with the gut alone does not establish that it works.31
Has an oral BPC-157 study been registered?
A ClinicalTrials.gov record describes a planned early study comparing BPC-157 tablets with placebo in an estimated 42 healthy volunteers, including measures of safety and what happens to the substance in the body. As checked on 6 November 2026, the registry status is unknown, it was last verified in 2015 and no results are posted. A plan and estimated enrolment do not prove the study was completed, how much was absorbed, or whether a current capsule helps an injury or gut condition. In its July 2026 review the US FDA said it had not identified human pharmacokinetic data after oral or under-the-skin administration.21
What do animal and other human studies tell us?
One rat study used BPC-157 in drinking water in an experimental oesophageal-inflammation model. Another study measured BPC-157 and related material after intravenous and intramuscular administration in rats and dogs. These are different routes, formulations and outcomes; they do not establish oral absorption or comparative benefit in people. The small human knee report involved an injection into the joint, not a comparison with capsules or an under-the-skin injection. A separate early ulcerative-colitis report used a rectal formulation. Follow the human-evidence guide and the gut-study guide for what those reports did and did not show.431
Is an injection necessarily better absorbed or safer?
An injection avoids the digestive tract, but into a joint, into a muscle, under the skin and into a vein are different routes. Absorption, distribution and risks cannot be assumed equal. The animal intramuscular measurements do not establish absorption from a human under-the-skin product. Injection also brings route-specific concerns such as sterility and local reactions, while an oral product has its own formulation and quality questions. There is not enough comparative human evidence to rank these products for effectiveness or overall safety. See local versus systemic effects and how to recognise concerning injection-site symptoms.31
Do “arginate”, “acetate” or “stable” settle the question?
These terms can describe different forms or product claims, but a name alone does not demonstrate that a finished product releases the same amount, reaches the bloodstream or works better. A stability claim should identify the tested formulation, conditions and measured outcome. We did not find a reliable human head-to-head absorption comparison in the sources checked; that is a limit of this search, not proof no such data could ever exist. A certificate of analysis can answer some product questions but not prove clinical benefit: see what a certificate can show.1
Where should I go next?
For ongoing digestive symptoms or an injury, a clinician can help establish the cause and discuss options with evidence for that condition. The BPC-157 profile explains the US policy distinction and the wider evidence. To understand why some peptide medicines can be made into tablets, read how oral peptides reach the body.1
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- BPC-157-related bulk drug substances: July 2026 briefing documentU.S. Food and Drug Administration · Regulator review of a meeting abstract and other evidence
- PCO-02: safety and pharmacokinetics trial (NCT02637284)ClinicalTrials.gov / US National Library of Medicine · Clinical trial registry record, last verified 2015
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogsFrontiers in Pharmacology / PubMed · Primary animal pharmacokinetic study, abstract and figures
- Stable gastric pentadecapeptide BPC 157 in experimental rat oesophagitisJournal of Pharmacological Sciences / J-STAGE · Animal experiment, 2006